ArticleBMC cancer2009
Identification of proteins involved in neural progenitor cell targeting of gliomas.
Article in BMC cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Significance of the association between hypoxia and pyroptosis-related genes in the prognostic prediction of glioblastoma: insights from model construction and validation.Translational cancer research · 2025Article
- Targeting the neural stem cells in subventricular zone for the treatment of glioblastoma: an update from preclinical evidence to clinical interventions.Stem cell research & therapy · 2023Review
- Astrocytes express aberrant immunoglobulins as putative gatekeeper of astrocytes to neuronal progenitor conversion.Cell death & disease · 2023Article
- The Subventricular Zone in Glioblastoma: Genesis, Maintenance, and Modeling.Frontiers in oncology · 2022Review
- TAM Receptor Pathways at the Crossroads of Neuroinflammation and Neurodegeneration.Disease markers · 2019Review
- The role of TAM family receptors and ligands in the nervous system: From development to pathobiology.Pharmacology & therapeutics · 2018Review
- Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment.International journal of molecular sciences · 2018Review
- Article
- Human Neural Stem Cell Biodistribution and Predicted Tumor Coverage by a Diffusible Therapeutic in a Mouse Glioma Model.Stem cells translational medicine · 2017Article
- Molecular insights of Gas6/TAM in cancer development and therapy.Cell death & disease · 2017Review
- Axl as a mediator of cellular growth and survival.Oncotarget · 2014Review
- Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.International journal of radiation oncology, biology, physics · 2013Article
- Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1.Nature medicine · 2012Article
- Contact and encirclement of glioma cells in vitro is an intrinsic behavior of a clonal human neural stem cell line.PloS one · 2012Article
- Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.PloS one · 2012Article
- Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations.Clinical and experimental medicine · 2011Article
- Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol.Journal of proteome research · 2011Article
- CD81 inhibits the proliferation of astrocytes by inducing G(0)/G (1) arrest in vitro.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma are highly aggressive tumors with an average survival time of 12 months with currently available treatment. We have previously shown that specific embryonic neural progenitor cells (NPC) have the potential to target glioma growth in the CNS of rats. The neural progenitor cell treatment can cure approximately 40% of the animals with malignant gliomas with no trace of a tumor burden 6 months after finishing the experiment. Furthermore, the NPCs have been shown to respond to signals from the tumor environment resulting in specific migration towards the tumor. Based on these results we wanted to investigate what factors could influence the growth and progression of gliomas in our rodent model.
methodsUsing microarrays we screened for candidate genes involved in the functional mechanism of tumor inhibition by comparing glioma cell lines to neural progenitor cells with or without anti-tumor activity. The expression of candidate genes was confirmed at RNA level by quantitative RT-PCR and at the protein level by Western blots and immunocytochemistry. Moreover, we have developed in vitro assays to mimic the antitumor effect seen in vivo.
resultsWe identified several targets involved in glioma growth and migration, specifically CXCL1, CD81, TPT1, Gas6 and AXL proteins. We further showed that follistatin secretion from the NPC has the potential to decrease tumor proliferation. In vitro co-cultures of NPC and tumor cells resulted in the inhibition of tumor growth. The addition of antibodies against proteins selected by gene and protein expression analysis either increased or decreased the proliferation rate of the glioma cell lines in vitro.
conclusionThese results suggest that these identified factors might be useful starting points for performing future experiments directed towards a potential therapy against malignant gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.